GB-5267
Metastatic Ovarian Cancer
PreclinicalIND 'study may proceed' granted Dec 2025; 50/50 collaboration
Key Facts
Indication
Metastatic Ovarian Cancer
Phase
Preclinical
Status
IND 'study may proceed' granted Dec 2025; 50/50 collaboration
Company
About Generate Biomedicines
Generate Biomedicines is at the forefront of integrating machine learning, biological engineering, and medicine to create a new paradigm in drug discovery called Generative Biology™. Its proprietary platform learns from millions of proteins to generate novel therapeutics with specific functions, drastically accelerating R&D. The company has advanced a Phase 3 anti-TSLP antibody for severe asthma, built a diverse preclinical pipeline in oncology and immunology, and secured strategic collaborations, positioning it as a leader in AI-driven biotherapeutics.
View full company profile